Therapeutic Cancer Vaccines

Surgical Oncology Clinics of North America

Volumn 16, Issue 4, 2007, Pages 819-831

  Morris, Lilah F ^a   Ribas, Antoni ^a,b,c  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; CANCER VACCINE; CANVAXIN; DACARBAZINE; DENDRITIC CELL VACCINE; DNA VACCINE; GANGLIOSIDE GM2; GLYCOPROTEIN GP 96; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HEAT SHOCK PROTEIN; MELACINE; PHOSPHORYL LIPID A; PROVENGE; QS 21; T LYMPHOCYTE RECEPTOR; VIRUS VACCINE;

ADJUVANT THERAPY; ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; BACTERIAL INFECTION; BINDING AFFINITY; CANCER; CANCER IMMUNIZATION; CANCER STAGING; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG MEGADOSE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; LOW DRUG DOSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; REVIEW; SOLID TUMOR; TREATMENT RESPONSE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; HLA ANTIGENS; HUMANS; IMMUNOGLOBULIN IDIOTYPES; NEOPLASMS;

EID: 36048945455     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2007.07.007     Document Type: Review

References (52)

1. Wiemann B., and Starnes C.O. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 64 (1994) 529-564
2. Mocellin S., Semenzato G., Mandruzzato S., et al. Part II: vaccines for haematological malignant disorders. Lancet Oncol 5 12 (2004) 727-737
3. Timmerman J. Immunotherapy for lymphomas. Int J Hematol 77 5 (2003) 444-455
4. Rosenberg S.A. Progress in human tumor immunology and immunotherapy. Nature 411 (2001) 380-384
5. Miller A., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 47 1 (1981) 207-214
6. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
7. Rosenberg S., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 9 (2004) 909-915
8. Nagorsen D., and Thiel E. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res 12 10 (2006) 3064-3069
9. Rosenberg S., Yang J.C., Schwartzentruber D.J., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4 3 (1998) 321-324
10. Mocellin S., Mandruzzato S., Bronte V., et al. Cancer vaccines: pessimism in check. Nat Med 10 12 (2004) 1278-1280
11. Mocellin S., Mandruzzato S., Bronte V., et al. Part I: vaccines for solid tumors. Lancet Oncol 5 (2004) 681-689
12. Copier J., and Dalgleish A. Overview of tumor cell-based vaccines. Int Rev Immunol 25 (2006) 297-319
13. Sondak V., and Sosman J.A. Results of clinical trails with an allogeneic melanoma tumor cell lysate vaccine: melacine. Semin Cancer Biol 13 (2003) 409-415
14. Sondak V., Liu P.Y., Tuthill R.J., et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 20 8 (2002) 2058-2066
15. Mitchell M., Abrams J., Thompson J.A., et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon alfa-2b compared with high-dose interferon alfa-2b for resected stage III cutaneous melanoma. J Clin Oncol 25 16 (2007) 2078-2085
16. Morton D., Hsueh E.C., Essner R., et al. Prolonged survival of patients receiving active immunotherapy wiht canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 236 4 (2002) 438-449
17. Morton D., Mozzillo N., Thompson J.F., et al. An international, randomized, phase III trial of bacillus Clamette-Guerin (BCG) plus allogenic melanoma vaccine (MCV) or placebo after complete resection of melanoma mestatic to regional or distant sites. 2007 ASCO Annual Meeting Proceedings, Part I. J Clin Oncol 25 Suppl 18S (2007) 8508
18. Jocham D., Richter A., Hoffmann L., et al. Adjuvant autologous renal tumor cell vaccine and risk of tumor progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363 (2004) 594-599
19. Uyl-de Groot C., Vermorken J.B., Hanna Jr. M.G., et al. Immunotherapy with autologous tumor cell-BCG vaccine in paitents with colon cancer: a prospective study of medical and economic benefits. Vaccine 23 (2005) 2379-2387
20. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev 188 (2002) 147-154
21. Dranoff G., Jaffee E., Lazenby A., et al. Vaccination with irradiated tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90 (1993) 3539-3543
22. Soiffer R., Lynch T., Mihm M., et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A 95 (1998) 13141-13146
23. Hege K., Jooss K., and Pardoll D. GM-CSF gene-modified cancer cell immunotherapies: of mice and men. Int Rev Immunol 25 (2006) 321-352
24. Slingluff C., Petroni G.R., Yamschchikov G.V., et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 22 (2004) 4474-4485
25. Parmiani G., Castelli C., Dalerba P., et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?. J Natl Cancer Inst 94 11 (2002) 805-818
26. Gilboa E. DC-based cancer vaccines. J Clin Invest 117 5 (2007) 1195-1203
27. Saito H., Frleta D., Dubsky P., et al. Dendritic cell-based vaccination against cancer. Hematol Oncol Clin North Am 20 (2006) 689-710
28. Schadendorf D., Ugurel S., Schuler-Thurner B., et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatament of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17 (2006) 563-570
29. Small E., Schellhammer P.F., Higano C.S., et al. Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormon refractory prostate cancer. J Clin Oncol 24 19 (2006) 3089-3094
30. Kirkwood J., Ibrahim J.G., Sasman J.A., et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19 9 (2001) 2370-2380
31. Castelli C., Rivoltini L., Rini F., et al. Heat shock proteins: biological functions and clinical applications as personalized vaccines for human cancer. Cancer Immunol Immunother 53 (2004) 227-233
32. Srivastava P., DeLeo A.B., and Old L.J. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci U S A 83 (1986) 3407-3411
33. Richards J., Testori A., Whitman E., et al. Autologous tumor-derived HSPPC-96 vs. physician's choice (PC) in a randomized phase III trial in stage IV melanoma. J Clin Oncol 24 18S (2006) 8002
34. Srinivasan R., and Wolchok J.D. Tumor antigens for cancer immunotherapy: therapeutic potential of xenogenic DNA vaccines. J Transl Med 2 1 (2004) 12
35. Stan R., Wolchok J.D., and Cohen A.D. DNA vaccines against cancer. Hematol Oncol Clin North Am 20 (2006) 613-636
36. Bergman P., McKnight J., Novosad A., et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 9 (2003) 1284-1290
37. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A 93 (1996) 11341-11348
38. Arlen P., Dahut W.L., and Gulley J.L. Immunotherapy for prostate cancer: what's the future?. Hematol Oncol Clin North Am 20 (2006) 965-983
39. DiPaola R., Plante M., Kaufman H., et al. A phase I trial of Pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med 4 (2006) 1
40. Kaufman H., Wang W., Manola J., et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the eastern cooperative oncology group. J Clin Oncol 22 11 (2004) 2122-2132
41. Kaufman H., Wang W., Manola J., et al. Phase II prime/boost vaccination using poxviruses expressing PSA in hormone dependent prostate cancer: follow-up clinical results from ECOG 7897. J Clin Oncol 23 16S (2005) 4501
42. Gattitoni L., Powell D.J., Rosenberg S.A., et al. Adoptive immunotherapy for cancer: building on success. Nat Immunol 6 (2006) 383-393
43. Kradin R., Kurnick J.T., Lazarus D.S., et al. Tumor-infiltrating lymphocytes and interleukin-2 in the treatment of advanced cancer. Lancet 1 8638 (1989) 577-580
44. Rosenberg S., Yannelli J.R., Yang J.C., et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphoctyes and interleukin 2. J Natl Cancer Inst 86 15 (1994) 1159-1166
45. Figlin R., Thompson J.A., Bukowski R.M., et al. Multicenter, randomized, phase III trial of CD8+ tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 17 8 (1999) 2521-2529
46. Dudley M., Wunderlich J.R., Yang J.C., et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 25 3 (2002) 243-251
47. Dudley M.E., Wunderlich J., Robbins P.F., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 5594 (2002) 850-854
48. Dudley M., Wunderlich J.R., Yang J.C., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23 10 (2005) 2346-2357
49. Kershaw M., Westwood J.A., Parker L.L., et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12 20 (2006) 6106-6115
50. Morgan R., Dudley M.E., Wunderlich J.R., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006) 126-129
51. Itoh K., and Yamada A. Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci 97 10 (2006) 970-976
52. Parmiani G., De Filippo A., Novellino L., et al. Unique tumor antigens: immunobiology and use in clinical trials. J Immunol 178 (2007) 1975-1979